These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 34128999

  • 1. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
    Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R.
    JAMA; 2021 Jun 15; 325(23):2348-2356. PubMed ID: 34128999
    [Abstract] [Full Text] [Related]

  • 2. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
    Ailani J, McAllister P, Winner PK, Chakhava G, Krog Josiassen M, Lindsten A, Sperling B, Ettrup A, Cady R.
    BMC Neurol; 2022 Jun 03; 22(1):205. PubMed ID: 35659622
    [Abstract] [Full Text] [Related]

  • 3. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
    McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R.
    J Headache Pain; 2022 Feb 07; 23(1):22. PubMed ID: 35130832
    [Abstract] [Full Text] [Related]

  • 4. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
    Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM.
    JAMA; 2019 Nov 19; 322(19):1887-1898. PubMed ID: 31742631
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ, Vasudeva R, Krege JH, Rathmann SS, Doty E, Vargas BB, Magis D, Komori M.
    Headache; 2020 Sep 19; 60(8):1601-1615. PubMed ID: 32634275
    [Abstract] [Full Text] [Related]

  • 6. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
    Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.
    Cephalalgia; 2019 Aug 19; 39(9):1075-1085. PubMed ID: 31234642
    [Abstract] [Full Text] [Related]

  • 7. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R.
    Headache; 2021 May 19; 61(5):766-776. PubMed ID: 34013992
    [Abstract] [Full Text] [Related]

  • 8. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB, Munjal S, Brand-Schieber E, Rapoport AM.
    Headache; 2018 May 19; 58(5):676-687. PubMed ID: 29878341
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B.
    Lancet Neurol; 2022 Jul 19; 21(7):597-607. PubMed ID: 35716692
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ, Bose R, Jion YI.
    Headache; 2024 Jul 19; 64(7):810-824. PubMed ID: 38785386
    [Abstract] [Full Text] [Related]

  • 12. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.
    Cady R, Lipton RB, Buse DC, Josiassen MK, Lindsten A, Ettrup A.
    J Headache Pain; 2022 Jul 28; 23(1):91. PubMed ID: 35902796
    [Abstract] [Full Text] [Related]

  • 13. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
    Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J.
    J Headache Pain; 2020 Oct 06; 21(1):120. PubMed ID: 33023473
    [Abstract] [Full Text] [Related]

  • 14. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
    Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B.
    Eur J Neurol; 2023 Apr 06; 30(4):1089-1098. PubMed ID: 36583633
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
    Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z, Liu J, Moon HS, Tan G, Yang Q, McGrath D, Hanna M, Stock DA, Gao Y, Croop R, Lu Z.
    Lancet Neurol; 2023 Jun 06; 22(6):476-484. PubMed ID: 37210098
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
    Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ.
    Headache; 2019 Apr 06; 59(4):509-517. PubMed ID: 30698272
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lipton RB, Thiry A, Morris BA, Croop R.
    J Pain Res; 2024 Apr 06; 17():2431-2441. PubMed ID: 39070853
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ubrogepant for the Treatment of Migraine.
    Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A.
    N Engl J Med; 2019 Dec 05; 381(23):2230-2241. PubMed ID: 31800988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.